Hints and tips:
Related Special Reports
...The first three sources are not the exclusive realm of knowledge industries such as tech or pharma....
...Astellas said on Monday that it would use cash and loans to buy the New Jersey-based company, formerly known as Ophthotech, for $40 a share, representing a premium of 22 per cent to the US company’s closing...
...What that shows is that big companies have shied away from doing mega deals but smaller acquisitions have gone ahead as they probably posed less of a threat....
...“It is not at all clear that Merck is doing anything other than extending its monopoly power over the drug,” Warren said....
...Doing business with Communist China presents a unique, substantial, pressing risk that warrants dedicated reporting. 2....
...Nisbet describes it as a “rethink” and says she would like to steer the focus towards artists — “often overlooked in the business of doing everything else”....
...Anderson, who considers as his mentor Harry Markopolos, the investigator known for sounding the alarm on Bernard Madoff’s Ponzi scheme, founded the business six years ago....
...“People were thinking that I’m trying to go into the pharma business [as] window dressing for my tobacco business,” he says. He is accustomed to receiving a frosty reception from scientists....
...fast as we can”....
...Creditors could miss the stable cash flows generated by the consumer business when the pharma-led business faces challenges from loss of exclusivity from blockbuster drugs, say some critics....
...Some campaigners have criticised the pay packets for vaccine maker chief executives, accusing the companies of unfairly profiting from the pandemic and not doing enough to ensure low-cost access to jabs...
...Regeneron, though, is hardly a mom-and-pop business. It has a market value of $60bn....
...Losing the pharma licence might limit SpectrumX to hand gels and detox tunnels....
...Like all large pharma companies, Merck’s business development team maintains a long list of potential targets, ranging from smaller biotechs with exciting but unproven drugs to larger companies with medicines...
...Investors are being asked to forgo about £60m to avoid doing business with a company whose main product kills people. That would be short-sighted and simplistic....
...attendees snapped pictures of the scene and texted it to colleagues, thankful it wasn’t their own book of business....
...BioNTech needed to make money from its first product to plough back into the business....
...“In 2009-10, pharma companies were priced as if they were going to go out of business, as if they were never going to have a [new] drug again,” he says....
...Yet by 2005, when Rahul Singhvi took over as chief executive, the women’s health business was being derailed by competition and concerns that oestrogen treatments increased the risk of breast cancer....
...The company formerly known as Valeant — which two years ago rebranded itself as Bausch Health after a string of scandals over pricing and accounting irregularities — is spinning off its eye-care business...
...“When the chips are down, you worry about doing the best for mankind.”...
...dismissed fines as a cost of doing business....
...But she hopes the sheer fact of people going to prison will deter other drugmakers, which may have previously accepted fines as a cost of doing business....
...“They are nervous that their data is the big value of their business and they would be giving it away,” he says....
...J&J is still respected as capable of doing its job — including creating life-saving drugs — but it needs to take action to address questions about its character, he said....
International Edition